Display options
Cite
Herbert MK, Aerts MB, Beenes M, et al. CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders. Front Neurol. 2015;6:91doi: 10.3389/fneur.2015.00091.
Herbert, M. K., Aerts, M. B., Beenes, M., Norgren, N., Esselink, R. A., Bloem, B. R., Kuiperij, H. B., & Verbeek, M. M. (2015). CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders. Frontiers in neurology, 691. https://doi.org/10.3389/fneur.2015.00091
Herbert, Megan K, et al. "CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders." Frontiers in neurology vol. 6 (2015): 91. doi: https://doi.org/10.3389/fneur.2015.00091
Herbert MK, Aerts MB, Beenes M, Norgren N, Esselink RA, Bloem BR, Kuiperij HB, Verbeek MM. CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders. Front Neurol. 2015 May 05;6:91. doi: 10.3389/fneur.2015.00091. eCollection 2015. PMID: 25999911; PMCID: PMC4419719.
Copy Download .nbib Format: NLM
Share it on

Front Neurol. 2015 May 05;6:91. doi: 10.3389/fneur.2015.00091. eCollection 2015.

CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders.

Frontiers in neurology

Megan K Herbert, Marjolein B Aerts, Marijke Beenes, Niklas Norgren, Rianne A J Esselink, Bastiaan R Bloem, H Bea Kuiperij, Marcel M Verbeek

Affiliations

  1. Department of Neurology and Parkinson Center, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre , Nijmegen , Netherlands ; Department of Laboratory Medicine, Radboud University Medical Centre , Nijmegen , Netherlands.
  2. Department of Neurology and Parkinson Center, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre , Nijmegen , Netherlands ; Parkinson Center , Nijmegen , Netherlands.
  3. UmanDiagnostics , Umeå , Sweden.
  4. Department of Neurology and Parkinson Center, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre , Nijmegen , Netherlands ; Department of Laboratory Medicine, Radboud University Medical Centre , Nijmegen , Netherlands ; Parkinson Center , Nijmegen , Netherlands.

PMID: 25999911 PMCID: PMC4419719 DOI: 10.3389/fneur.2015.00091

Abstract

The differentiation between multiple system atrophy (MSA) and Parkinson's disease (PD) is difficult, particularly in early disease stages. Therefore, we aimed to evaluate the diagnostic value of neurofilament light chain (NFL), fms-like tyrosine kinase ligand (FLT3L), and total tau protein (t-tau) in cerebrospinal fluid (CSF) as biomarkers to discriminate MSA from PD. Using commercially available enzyme-linked immunosorbent assays, we measured CSF levels of NFL, FLT3L, and t-tau in a discovery cohort of 36 PD patients, 27 MSA patients, and 57 non-neurological controls and in a validation cohort of 32 PD patients, 25 MSA patients, 15 PSP patients, 5 CBS patients, and 56 non-neurological controls. Cut-offs obtained from individual assays and binary logistic regression models developed from combinations of biomarkers were assessed. CSF levels of NFL were substantially increased in MSA and discriminated between MSA and PD with a sensitivity of 74% and specificity of 92% (AUC = 0.85) in the discovery cohort and with 80% sensitivity and 97% specificity (AUC = 0.94) in the validation cohort. FLT3L levels in CSF were significantly lower in both PD and MSA compared to controls in the discovery cohort, but not in the validation cohort. t-tau levels were significantly higher in MSA than PD and controls. Addition of either FLT3L or t-tau to NFL did not improve discrimination of PD from MSA above NFL alone. Our findings show that increased levels of NFL in CSF offer clinically relevant, high accuracy discrimination between PD and MSA.

Keywords: FLT3 ligand; Parkinson’s disease; cerebrospinal fluid; multiple system atrophy; neurofilament light chain

References

  1. Acta Neurol Scand. 2006 Sep;114(3):205-9 - PubMed
  2. Parkinsonism Relat Disord. 2012 Jan;18(1):69-72 - PubMed
  3. Arch Neurol. 2012 Nov;69(11):1445-52 - PubMed
  4. Lancet Neurol. 2009 Dec;8(12):1128-39 - PubMed
  5. Nature. 1996 Oct 24;383(6602):716-9 - PubMed
  6. Ann Neurol. 2011 Mar;69(3):570-80 - PubMed
  7. Neurology. 2008 Aug 26;71(9):670-6 - PubMed
  8. J Neurol. 2015 Feb;262(2):346-56 - PubMed
  9. Mol Cell Proteomics. 2015 Mar;14(3):544-55 - PubMed
  10. Eur J Neurol. 2008 Apr;15 Suppl 1:14-20 - PubMed
  11. JAMA Neurol. 2013 Oct;70(10):1277-87 - PubMed
  12. Nat Rev Neurol. 2013 Mar;9(3):131-40 - PubMed
  13. Ther Adv Neurol Disord. 2010 Jul;3(4):249-63 - PubMed
  14. Mov Disord. 2006 Jun;21(6):809-15 - PubMed
  15. Neurosci Lett. 2006 May 1;398(1-2):44-9 - PubMed
  16. Cancer Res. 1992 Oct 1;52(19):5368-72 - PubMed
  17. Ann Neurol. 2003;54 Suppl 5:S15-9 - PubMed
  18. Neurology. 1996 Jul;47(1):1-9 - PubMed
  19. Parkinsonism Relat Disord. 2014 Apr;20(4):382-7 - PubMed
  20. Proc Natl Acad Sci U S A. 1995 May 23;92(11):5087-91 - PubMed
  21. Brain. 2002 Apr;125(Pt 4):861-70 - PubMed
  22. Cytokine Growth Factor Rev. 1998 Mar;9(1):37-48 - PubMed
  23. Parkinsonism Relat Disord. 2001 Sep;8(1):23-31 - PubMed
  24. J Neurol Sci. 1997 Feb 12;145(2):205-11 - PubMed
  25. Mov Disord. 2014 Sep;29(10):1319-22 - PubMed
  26. Neurology. 2001 Nov;57(10 Suppl 3):S11-26 - PubMed
  27. Mov Disord. 2014 Jul;29(8):1019-27 - PubMed
  28. PLoS One. 2012;7(2):e31146 - PubMed
  29. Parkinsonism Relat Disord. 2010 Feb;16(2):142-5 - PubMed
  30. Neurobiol Aging. 2007 May;28(5):742-7 - PubMed
  31. Mol Cell Neurosci. 2001 Oct;18(4):381-93 - PubMed
  32. Lancet Neurol. 2006 Jun;5(6):525-35 - PubMed
  33. Lancet Neurol. 2009 Dec;8(12):1172-8 - PubMed
  34. Parkinsonism Relat Disord. 2007 Dec;13(8):480-2 - PubMed
  35. Neurobiol Aging. 2009 Sep;30(9):1477-82 - PubMed
  36. J Neurol. 2009 Apr;256(4):615-9 - PubMed

Publication Types